Open AccessPharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations
Author(s) -
Xue Li,
Xinyi Tan,
Xuejun Cui,
Moon-Sik Yang,
Chao Chen,
Xiaoyun Chen
Publication year - 2021
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s329690
Subject(s) - tenofovir alafenamide , medicine , pharmacokinetics , genotype , tenofovir , single nucleotide polymorphism , chinese population , polymorphism (computer science) , renal function , population , pharmacology , human immunodeficiency virus (hiv) , gastroenterology , traditional medicine , genetics , antiretroviral therapy , biology , viral load , immunology , gene , environmental health
Tenofovir alafenamide fumarate (TAF) was approved for HBV treatment in China in 2018. Despite higher antiviral efficacy and less impact on renal function and bone mineral density, the pharmacokinetic profiles of TAF are highly variable. The objectives of this study were to investigate the pharmacokinetics of TAF in the Chinese population and explore the associations between TAF and genetic polymorphisms and non-genetic factors.